Abstract
Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease caused by diffuse inflammation and fibrosis that can involve the entire biliary tree. It is a progressive disorder which can ultimately lead to biliary cirrhosis, portal hypertension and hepatic failure. PSC is a complex genetic disorder with male predominance. Environmental predisposing factors include non-smoking. It is closely associated with inflammatory bowel disease (IBD), particularly ulcerative colitis, which occurs in about two thirds of PSC cases. Recent studies have suggested that PSC-IBD is a separate disease entity from IBD alone with distinctive genetic and phenotypic characteristics. Most PSC patients are asymptomatic at presentation; clinical symptoms include fatigue, jaundice, weight loss, right upper quadrant pain and pruritis. Serum biochemical tests indicate cholestasis, and diagnosis is usually established by cholangiography. In symptomatic patients, median survival from presentation to death or liver transplantation is about 12 years. It is a premalignant condition, and the majority of deaths are from malignancy, particularly cholangiocarcinoma or colonic cancer. PSC has no curative treatment. Medical treatment with ursodeoxycholic acid may slow progression of the disease and reduce colonic dysplasia, though trials lack statistical significance. Liver transplantation is the only option in young patients with PSC and advanced liver disease.
References
1.
Hoffman CEE: Verschluss der Gallenwege durch Verdickung der Wandungen. Arch Pathol Anat Physiol 1867;39:206-215.
2.
Broome U, Olsson R, Loof L, et al: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615.
3.
Williamson KD, Chapman RW: Primary sclerosing cholangitis; in Warrell DA, Cox T, Firth J (eds): Oxford Textbook of Medicine, ed 5 (electronic resource). Oxford, Oxford University Press, 2010 (updated Nov 2012), chapt 15.21.4.
4.
Ngu JH, Gearry RB, Wright AJ, et al: Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011;9:1092-1097; quiz e135.
5.
Boonstra K, Beuers U, Ponsioen CY: Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181-1188.
6.
Lindkvist B, Benito de Valle M, Gullberg B, et al: Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010;52:571-577.
7.
Mitchell SA, Thyssen M, Orchard TR, et al: Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002;51:567-573.
8.
van Erpecum KJ, Smits SJ, van de Meeberg PC, et al: Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996;110:1503-1506.
9.
Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al: Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996;110:1496-1502.
10.
Melum E, Franke A, Schramm C, et al: Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011;43:17-19.
11.
Liu JZ, Hov JR, Folseraas T, et al: Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670-675.
12.
Hirschfield GM, Karlsen TH, Lindor KD, et al: Primary sclerosing cholangitis. Lancet 2013;382:1587-1599.
13.
Alswat K, Al-Harthy N, Mazrani W, et al: The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012;107:56-63.
14.
Bjornsson E, Chari S, Silveira M, et al: Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011;18:198-205.
15.
Mendes FD, Jorgensen R, Keach J, et al: Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006;101:2070-2075.
16.
Parhizkar B, Mohammad Alizadeh AH, Asadzadeh Aghdaee H, et al: Primary sclerosing cholangitis associated with elevated immunoglobulin-G4: a preliminary study. ISRN Gastroenterol 2012;2012:325743.
17.
Alderlieste YA, van den Elzen BD, Rauws EA, et al: Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009;79:220-228.
18.
O'Toole A, Alakkari A, Keegan D, et al: Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:439-441.
19.
Schrumpf E, Elgjo K, Fausa O, et al: Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980;15:689-697.
20.
Olsson R, Danielsson A, Jarnerot G, et al: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-1323.
21.
Loftus EV Jr, Harewood GC, Loftus CG, et al: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-96.
22.
Sano H, Nakazawa T, Ando T, et al: Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011;18:154-161.
23.
Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al: Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2270-2276.
24.
Halliday JS, Djordjevic J, Lust M, et al: A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis 2012;6:174-181.
25.
Marelli L, Xirouchakis E, Kalambokis G, et al: Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011;60:1224-1228.
26.
Moncrief KJ, Savu A, Ma MM, et al: The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation - a single-centre experience. Can J Gastroenterol 2010;24:40-46.
27.
Papatheodoridis GV, Hamilton M, Mistry PK, et al: Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998;43:639-644.
28.
Jorgensen KK, Grzyb K, Lundin KE, et al: Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012;18:536-545.
29.
Angulo P, Grandison GA, Fong DG, et al: Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180-188.
30.
Campbell MS, Lichtenstein GR, Rhim AD, et al: Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int 2005;25:311-316.
31.
European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
32.
Collier JD, Ninkovic M, Compston JE: Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50(suppl 1):i1-i9.
33.
Boonstra K, Weersma RK, van Erpecum KJ, et al: Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-2055.
34.
Bergquist A, Ekbom A, Olsson R, et al: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327.
35.
Al Mamari S, Djordjevic J, Halliday JS, et al: Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013;58:329-334.
36.
Lindstrom L, Hultcrantz R, Boberg KM, et al: Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013;11:841-846.
37.
Broome U, Lofberg R, Veress B, et al: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-1408.
38.
Soetikno RM, Lin OS, Heidenreich PA, et al: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54.
39.
Jess T, Simonsen J, Jørgensen KT, et al: Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375- 381.e1.
40.
Lindstrom L, Lapidus A, Ost A, et al: Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum 2011;54:1392-1397.
41.
Braden B, Halliday J, Aryasingha S, et al: Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012;10:303-308.
42.
Chapman R, Fevery J, Kalloo A, et al: Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
43.
Jorgensen KK, Lindstrom L, Cvancarova M, et al: Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012;47:1021-1029.
44.
Fevery J, Verslype C, Lai G, et al: Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007;52:3123-3135.
45.
Boberg KM, Bergquist A, Mitchell S, et al: Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-1211.
46.
Moreno Luna LE, Kipp B, Halling KC, et al: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-1072.
47.
Darwish Murad S, Kim WR, Harnois DM, et al: Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012;143:88-98.e3; quiz e14.
48.
Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
49.
Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
50.
Lindor KD, Kowdley KV, Luketic VA, et al: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-814.
51.
Ashraf I, Choudhary A, Arif M, et al: Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol 2012;31:69-74.
52.
Lindstrom L, Boberg KM, Wikman O, et al: High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012;35:451-457.
53.
Fosby B, Karlsen TH, Melum E: Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012;18:1-15.
54.
Vera A, Moledina S, Gunson B, et al: Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943-1944.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
